Medipharm Labs Corp T.LABS

With many smaller mj players facing major headwinds lately

[mdjbrown]

Labs shareholders should feel confident that Medipharm execs are keeping ahead of these headwinds including excise taxes

“Our cash balance at the end of Q4 was $18 million and the company has less than $3 million of debt. Contrary to many other cannabis companies, MediPharm is also up to date on cannabis excise duties, sales taxes and trade payables”


Looking forward to Q1 Financials as I expect even better improvements to the bottom line.

[QContinuum1]

With as much cash in the treasury, you have to believe that with it, and the positive guidance going forward, LABS is in good shape. Now imagine if you will that at the next Q call, Pidduck states that they're so confident in profitability, that they're taking 10 of the $18mil and buying back 125mil shares at 0.08, you want to be a stud, that's how.  You want to make existing

[mdjbrown]

That would certainly be a bold move QC1, but would it leave them exposed with the fluctuations in this crazy industry. I am very interested in Dronbiol sales in Q2 and beyond considering their Q1 windfall. "In 2023, we sold just under $100,000 of this product, mostly for partner R&D. At this point, in 2024, we have already shipped this product to 3 customers and our sales and open